Head to Head Analysis: PharmaCyte Biotech (OTCMKTS:PMCBD) and Compugen (NASDAQ:CGEN)

PharmaCyte Biotech (OTCMKTS:PMCBD) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Volatility and Risk

PharmaCyte Biotech has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Comparatively, Compugen has a beta of 2.64, indicating that its stock price is 164% more volatile than the S&P 500.

Profitability

This table compares PharmaCyte Biotech and Compugen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PharmaCyte Biotech	N/A	-49.09%	-43.39%
Compugen	N/A	-30.01%	-21.41%

Institutional & Insider Ownership

0.0% of PharmaCyte Biotech shares are owned by institutional investors. Comparatively, 12.2% of Compugen shares are owned by institutional investors. 9.5% of Compugen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for PharmaCyte Biotech and Compugen, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PharmaCyte Biotech	0	0	0	0	N/A
Compugen	0	0	2	0	3.00

Compugen has a consensus price target of $4.00, indicating a potential upside of 104.08%. Given Compugen’s higher possible upside, analysts clearly believe Compugen is more favorable than PharmaCyte Biotech.

Valuation and Earnings

This table compares PharmaCyte Biotech and Compugen’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PharmaCyte Biotech	N/A	N/A	-$3.83 million	N/A	N/A
Compugen	$33.46 million	5.07	-$18.75 million	($0.22)	-8.91

PharmaCyte Biotech has higher earnings, but lower revenue than Compugen.

Summary

Compugen beats PharmaCyte Biotech on 8 of the 9 factors compared between the two stocks.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.